Clinical Trial Update: Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) [Phase 3]

View source ↗

Summary

Phase 3 trial update on intravenous iloprost for symptomatic Raynaud's phenomenon in patients with systemic sclerosis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon Secondary to Systemic Sclerosis

Drugs mentioned

• Iloprost (iloprost)

Snippet

Sponsor: Civi Biopharma, Inc. | Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2025-05-25